ATAI LLY(confirmed) lilly to acquire ataibeckley to advance Therapies for treatment-resistant depression and other mental health conditions
ATAI LLY(confirmed) lilly to acquire ataibeckley to advance Therapies for treatment-resistant depression and other mental health conditions Eli Lilly - to pay $6.75 per share cash plus up to $2.5 per share in cvr - Deal valued at $2.8B upfront with up to $1B in cvr - Deal expected to close in Q3 subject to approvals